Labcorp Receives FDA Approval for BRAF Melanoma Companion Diagnostic
Product·2 articles across 2 outlets·◆ Primary source
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Labcorp has announced that the FDA has approved its companion diagnostic for patients with advanced melanoma. This diagnostic specifically supports patients carrying certain BRAF variants.
The approval marks a significant advancement in personalized medicine for melanoma treatment, allowing for better-targeted therapies based on genetic testing.
Labcorp
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma”
SEC Filing — Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma“The FDA has signed off on Labcorp’s companion diagnostic for patients with advanced melanoma carrying certain BRAF variants.”
fierce biotech — <a href="/medtech/labcorp-nabs-fda-green-light-braf-melanoma-diagnostic" hreflang="en">Labcorp nabs FDA green light for BRAF melanoma diagnostic </a>